Tag Archive for: Syncona

Resolution Therapeutics Announces £63.5 Million Series B Financing and Chair Appointment

/in

Financing to advance lead asset RTX001, an engineered, pro-regenerative macrophage therapy with first-in-class potential for end-stage liver disease, into the Phase I/II EMERALD study Proceeds also strengthen manufacturing capabilities and support macrophage therapy pipeline growth in inflammatory and fibrotic indications beyond liver disease Paul Sekhri, seasoned life sciences executive with decades of drug development and […]

Read more

iOnctura announces EUR80 million Series B financing to progress pipeline through Phase II trials

/in

• Led by new investor Syncona, with participation from the European Innovation Council Fund as well as existing investors • To progress pipeline of innovative, first-in-class, oral cancer treatments targeting neglected and hard-to-treat cancers • To accelerate development of lead asset roginolisib for treatment of uveal melanoma and a number of other oncology indications Geneva, […]

Read more

Trends in life science investments – Top take-aways from Anglonordic

/in

The first panel of the day, chaired by Mary Clark, our co-founder and CEO, saw a group of Europe’s leading investors – Hakan Goker, M Ventures; Maina Bhaman, Sofinnova Partners; Christian Elling, Lundbeckfonden; and Roel Bulthuis, Syncona – share sage advice for companies looking to raise funds, providing insights on the most important factors shaping […]

Read more

Optimum European Healthcare Investor Survey

/in ,

European investors continue actively investing in healthcare. The survey held in May 2020 includes responses from 24 of the most influential European VCs, investing approximately EUR 15.5 billion in aggregate in the Healthcare sector.

Read more